Skip to content
2000
Volume 14, Issue 5
  • ISSN: 1389-2010
  • E-ISSN: 1873-4316

Abstract

Drug development is a long and expensive process. It starts from the identification of a small molecule (hit compound) endowed with the ability to suppress a cellular or viral enzyme essential for the development of a given disease and proceeds through subsequent rounds of structural changes and optimization until the desired pharmacological properties are reached (lead compound). At any point of the hit-to-lead optimization process, it is of essence to monitor the behavior of the intermediate molecules with respect to their molecular targets. This involves precise mechanism of action studies as well as quantitative measurement of the performance of the compound against its target. Enzyme kinetic studies are thus an essential component of the drug development process. Relevant examples of the power of enzyme kinetics in the antiviral drug development process will be discussed in the context of anti-HIV chemotherapy.

Loading

Article metrics loading...

/content/journals/cpb/10.2174/138920101405131111105023
2013-06-01
2025-07-06
Loading full text...

Full text loading...

/content/journals/cpb/10.2174/138920101405131111105023
Loading

  • Article Type:
    Research Article
Keyword(s): Antiviral drugs; Enzyme kinetics; Inhibitors; SAR; Virtual screening
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test